Why the study?
GLP-1 receptor agonists improve glycemic control and cardiovascular outcomes, but their effects may be modified by the presence of heart failure.
Does the use of GLP-1 RAs improve outcomes and what are the risks in patients across the spectrum of heart failure?
Does the use of GLP-1 RAs improve outcomes and what are the risks in patients across the spectrum of heart failure?
This review challenges current views by recommending active heart failure screening prior to GLP-1 RA initiation and advising caution in patients with HFrEF due to potential adverse events.
No takes yet. Share an insight, caveat, or question.
GLP-1 RAs warrant caution in HF; leaves open optimal use pending dedicated trials.
Ferreira et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: